IMPT 514
Alternative Names: IMPT-514Latest Information Update: 26 Aug 2024
At a glance
- Originator ImmPACT Bio
- Class Antineoplastics; CAR-T cell therapies; Gene therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Lupus nephritis; Systemic lupus erythematosus
- Phase I Lymphoma
- Preclinical Multiple sclerosis